Acro

What Acro does

ACRO Biomedical Co., Ltd. (亞果生醫股份有限公司), founded in 2014 and headquartered in Kaohsiung, Taiwan, is a regenerative medicine company that develops medical-grade decellularized collagen biomaterials from animal tissue (primarily porcine SPF sources) using a proprietary Supercritical Carbon Dioxide (scCO2) Decellularization Technology Platform. The platform completely removes cells, fats, and non-collagen proteins while preserving the natural collagen scaffold and extracellular matrix architecture, producing highly biocompatible acellular matrices suitable for tissue regeneration. The company's product portfolio is organized under four sub-brands: ABCcolla® for medical devices spanning wound care, hemostasis, orthopedics, dentistry, ophthalmology, and scar management; ACRODERM for medical-grade consumer skincare; ACROPET for veterinary applications; and ACROTERM for tissue engineering research scaffolds. Its flagship Collagen Ophthalmic Matrix — described as the world's first scCO2 decellularized porcine corneal matrix — addresses the global shortage of donor corneas and has received Taiwan TFDA Class III approval (MOHW Medical Device No. 008155).

The company's business model combines direct sales in Taiwan with an international licensing/royalty model built on exclusive regional distribution partnerships, most notably the 10-year ASEAN exclusive agreement with CT Group/VGCT for the corneal matrix at approximately US$1,100 per unit with a US$10M minimum annual order guarantee and 10% per-unit royalty. Additional channel partners include Marubeni (Japan), Oculus Biomed (Australia, also a major institutional shareholder), DKSH (Vietnam), and Raptim Research (India, clinical trials). The company holds 48 medical device regulatory approvals globally and 92+ patents across 15+ countries. ACRO is listed on Taiwan's emerging stock market (興櫃, stock code 6748) under Chairman and CEO Dar-Jen Hsieh, with plans to transfer to the Taiwan Innovation Board in Q4 2026 to access growth capital for ASEAN expansion, clinical trials, and scaling of its full regenerative biomaterials portfolio.

Name

Acro

Legal name

ACRO Biomedical Co., Ltd.

Website

https://acrobiomedical.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

ACRO Biomedical (Taiwan) develops medical-grade decellularized collagen biomaterials using proprietary supercritical CO2 technology, serving hospitals, surgeons, and consumers across wound care, ophthalmology, orthopedics, dentistry, veterinary, and skincare markets.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

akta.pro secondary industries

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Tissue Engineering & Biomaterial Scaffolds (HLAMANAC)

Keywords

• Regenerative biomaterials
• Collagen medical devices
• Decellularized tissue scaffolds
• Wound care products
• Tissue engineering

Headquarters

HQ city

Kaohsiung

HQ country

Taiwan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Medical Device Sales: Direct sales of regulated collagen-based medical devices across wound care, orthopedics, dentistry, ophthalmology, and scar care. Products include ABCcolla® Collagen Matrix (Class II), Hemostatic Collagen Matrix (Class III), Collagen Ophthalmic Matrix (Class III), and ACRODERM skincare products. The company holds 48 regulatory approvals across multiple countries.
2. International Licensing & Royalty Revenue: Long-term exclusive distribution agreements with royalty structures. The 10-year ASEAN 10-country license with CT Group/VGCT includes $10 million in cumulative royalties plus 10% per-unit royalty on corneal matrix sales. Additional licensing revenue from Japan patent on hair follicle regeneration and other international partnerships.
3. Consumer Skincare Products (ACRODERM): Direct-to-consumer and retail sales of ACRODERM medical skincare line including cleansers, toners, serums, creams, masks, and gift sets. Products are sold through the company's own channels and at exhibitions and trade shows.
4. ACROPET Veterinary Medical Devices: Sales of veterinary collagen medical devices for pets including collagen membranes, wound dressings, corneal matrices, and bone fillers targeting veterinary clinics and pet owners.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Core offering

ACRO Biomedical develops and manufactures medical-grade regenerative biomaterials derived from animal tissues using its proprietary supercritical CO2 decellularization platform. Its portfolio includes ABCcolla® collagen-based medical devices for wound care, hemostasis, orthopedics, dentistry, ophthalmology (corneal matrix), and scar management, alongside ACRODERM medical skincare, ACROPET veterinary devices, and ACROTERM tissue engineering scaffolds for research.

Product overview

ACRO Biomedical Co., Ltd. (亞果生醫股份有限公司) is a regenerative medicine company specializing in decellularized collagen-based medical devices and biomedical materials. The company's core technology is its proprietary Supercritical CO2 Decellularization Platform, which removes cells and allergens from animal-derived tissues while preserving natural collagen scaffold structures. The product portfolio is organized under two main brands: ABCcolla® (亞比斯·可拉®) for medical devices and ACRODERM for medical aesthetics skincare. ABCcolla® medical devices span wound care (hemostatic collagen matrix, ADM scaffolds, wound dressings, scar care products), orthopedics (bone grafts, bone matrix), dentistry (collagen membranes, dental bone grafts), ophthalmology (collagen ophthalmic matrix for corneal reconstruction), and tissue engineering (collagen scaffolds for 3D bioprinting and organoid research). ACRODERM skincare line includes cleansing, exfoliating, moisturizing, and anti-aging products infused with biomedical-grade collagen. The company also offers ACROPET veterinary medical devices and ACROTERM research products for tissue engineering applications.

Differentiator

Problem solved

Functional benefit

Brands

• ABCcolla: Collagen-based medical device product line including wound care, bone grafts, and dermal matrices
• ACRODERM
• ACROPET
• ACROTERM

Products and services

• ABCcolla® Collagen Matrix Decellularized porcine collagen matrix processed via proprietary supercritical CO2 technology, preserving natural dermis collagen scaffolds. TFDA Class II medical device and USFDA 510(k) cleared; used for wound care and tissue regeneration.
• ABCcolla® Hemostatic Collagen Matrix Decellularized porcine collagen material for bleeding wound care. Promotes platelet aggregation and coagulation for hemostasis while maintaining a moist wound environment. TFDA Class III approved.
• Hemostatic ADM Scaffold Decellularized porcine collagen dermis scaffold indicated for absorbing wound exudates and maintaining moist wound environment; induces platelet aggregation for hemostasis on bleeding wounds. TFDA Class III approved.
• Hemostatic ADM Paste Decellularized porcine collagen gel for wound application, easy to apply to wounds of varying depths with excellent adhesive properties. Gradually resorbed by the body; facilitates platelet aggregation and coagulation. TFDA Class III approved.
• ABCcolla® Collagen Matrix Powder Collagen matrix in powder form processed by supercritical CO2 decellularization with a porous structure that absorbs tissue exudates. Indicated for irregular or deep wounds including trauma, diabetic ulcers, surgical wounds, and dental wounds.
• ABCcolla® Intranasal Splint Wound dressing derived from decellularized porcine dermis providing nasal tissue support and absorbing blood and nasal exudate after nasal surgery. Naturally biodegradable within 2-5 days. TFDA Class I.
• ABCcolla® Scar Spray Silicone spray containing high concentration of biomedical-grade collagen that forms a protective film on the stratum corneum. Shields against chemical, physical, and microbial invasion; contains hyaluronic acid. TFDA/CE/USFDA Class I.
• ABCcolla® Scar Gel Transparent scar care gel forming a protective barrier on the stratum corneum, containing aloe vera gel and hyaluronic acid to soften and moisturize scars. TFDA/CE/USFDA Class I.

Quantifiable outcome

• TFDA Class III medical device approvals obtained for 3 hemostatic products simultaneously — a new benchmark in Taiwan's medical device industry
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• CT Group / VGCT (Vietnam Gene & Cell Technology JSC)coreChannel Partner/ Reseller/ Distributor · 1 July 202510-year exclusive distribution agreement signed July 2025 for the 亞比斯·可拉膠原蛋白眼角膜基質 (Collagen Ophthalmic Matrix) covering all 10 ASEAN countries. VGCT is the exclusive distributor under the CT Group umbrella. Contract includes guaranteed minimum orders of US$10 million annually after Vietnamese regulatory approval, cumulative royalties of US$10 million, then 10% per-unit royalty. ACRO plans to establish a joint venture with CT Group in 2026 to expand再生醫材 product promotion across ASEAN.
• Raptim Research Pvt. Ltd.coreChannel Partner/ Reseller/ Distributor · 1 April 2025Indian clinical research organization (CRO) engaged to conduct a 150-patient corneal transplant clinical trial in India. Expected to complete within two years. Clinical data compliant with international GCP standards will support regulatory applications to Indian CDSCO, US FDA, and EU CE certification simultaneously.
• Prof. Kuan-Chang Chang (張光華教授)coreStrategic or Co-development Partner · 1 October 2024Academic collaboration with Prof. Kuan-Chang Chang's team at National Cheng Kung University to develop the ADM-based neuromorphic device combining ACRO's decellularized collagen biomembranes with semiconductor technology. This bioelectronic interface technology was featured on the cover of ACS Nano journal. Applications include neural repair, disease monitoring, and brain-machine interfaces.
• Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) / Development Center for Biotechnology (DCB)minorStrategic or Co-development Partner · 1 October 2024ACRO participated in the BioConnect: Australia-Taiwan Biotech Forum co-hosted by BPIPO, DCB, Southern Taiwan Science Park Bureau, and the Australian Office in Taipei. BPIPO leads Taiwan's biotech industry-academia collaboration initiatives.
• Oculus Biomed Pty Ltd (OBM)coreStrategic or Co-development Partner · 1 April 2024Australian biomedical company and ACRO's 4th largest institutional shareholder. OBM focuses on ophthalmic medical technology development with a global team of scientists. The two companies share the same vision for ophthalmic regenerative medicine. ACRO plans to collaborate with OBM for decellularized cartilage filling clinical trials in Australia, leveraging OBM's local regulatory, market, and networking expertise. OBM is preparing for an IPO.
• Marubeni Corporation (丸紅)minorGTM or Marketing Partner · 1 January 2024Japanese trading company partnership for market development in Japan. One of Japan's top five trading houses (五大貿易商圈). Partnership reflects growing international recognition of ACRO's technology.
• National Chung Hsing University — College of Veterinary MedicineminorStrategic or Co-development Partner · 1 January 2024Collaboration for decellularized organ regeneration research, specifically kidney regeneration studies. The university provides experimental facilities and post-operative monitoring for kidney transplant animal studies.
• Kaohsiung Medical UniversityminorStrategic or Co-development Partner · 1 January 2024Animal studies collaboration for kidney regeneration using scCO2 decellularization technology. In rabbit studies, transplanted kidneys successfully regained urine production within four weeks.
• Tung's Taichung MetroHarbor Hospital (童綜合醫院)minorStrategic or Co-development Partner · 1 January 2024Clinical research partner for conducting transplant surgeries in the decellularized kidney regeneration program.
• DKSH (大昌華嘉)minorChannel Partner/ Reseller/ Distributor · 1 January 2023Distribution partnership established in 2023 with DKSH to build Vietnam market channel infrastructure prior to the CT Group exclusive distribution agreement. DKSH's distribution expertise provided market entry support in Vietnam.

Scale indicators7 records

Recent moves7 records

Broad incumbents

• Integra LifeSciences: Established medical device company with a strong regenerative technologies portfolio including Integra Dermal Regeneration Template and wound matrices. Comparable on skin substitute/wound care product category, though much broader and more diversified across neurosurgery and orthopedics.
• Smith+Nephew: Global medical device company with advanced wound management and orthopedics franchises. Comparable on collagen-based wound care and skin substitute products (e.g., PICO, Oasis) addressing similar hospital end-markets as ACRO's hemostatic and wound healing portfolio.
• ConvaTec: Global medical products company with a substantial advanced wound care franchise (Avelle, Aquacel). Comparable on collagen-based and biologic wound dressings sold to hospitals and home care channels.
• Coloplast: Danish medical device leader in wound care and skin substitutes (e.g., Biatain). Comparable on collagen-containing wound dressings and biologic skin substitutes, though serves much broader geographies with established scale.

Direct peers

• MTF Biologics: Non-profit tissue bank producing allograft and acellular dermal matrix products for wound care, orthopedics, and sports medicine. Comparable on processed/decellularized collagen scaffolds sold through hospital channels.
• LifeNet Health: Non-profit tissue banking and regenerative medicine organization offering decellularized dermal matrices, allografts, and tissue-engineered products. Closely comparable technology base (decellularized tissue scaffolds) and overlap on wound care, orthopedic, and surgical applications.
• MiMedx Group: US-based regenerative medicine company using placental/amniotic tissue allografts for wound care, surgical recovery, and orthopedics. Directly comparable on regenerative biomaterials technology and hospital channel distribution for wound healing applications.
• Organogenesis: US-listed regenerative medicine company specializing in advanced wound care and surgical biologic products (Apligraf, Dermagraft, PuraPly). Directly comparable to ACRO as a tissue-based regenerative medicine business selling collagen/skin substitute medical devices to hospitals and wound care clinics.

Emerging players

• CorNeat Vision: Israeli ophthalmic medical device company developing synthetic corneal implants (CorNeat KPro) for corneal blindness. Directly comparable end-market (corneal blindness treatment) with a synthetic versus tissue-based approach.
• TissueTech: US regenerative medicine company using cryopreserved amniotic membrane and umbilical cord tissue products (AmnioFix, EpiFix) for wound healing and ophthalmology. Comparable on regenerative biomaterials sold into hospital ophthalmology and wound care markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/acrobiomedical
• LinkedInlinkedin.com/company/acrobiomedical

Compliance19 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acro